White Paper | December 5, 2013

Vaccine Potential And Preclinical Development Needs

Source: MPI Research
MPI

By Stephene Rose; Senior Study Director at MPI Research

Few medical advances have made as large an impact on world health as vaccines. Globally, Vaccines prevent approximately 10.5 million cases of infectious illness each year. 2.5 million child deaths are prevented from diphtheria, tetanus, pertussis, and measles annually through immunization (BIO). Despite these facts, infectious diseases are still the second leading cause of death worldwide, and new infectious diseases continue to emerge.

While traditionally thought of as a pure disease preventative, Vaccines can help the body to mount an immune response against any foreign body (antigen), including a cancer cell or a drug/chemical. Vaccines can be built using various antigens (e.g., viral, bacterial, DNA-based, peptide, or recombinant protein) in various forms (e.g., attenuated, replicating, non-replicating, live, or killed). The versatility and variety of vaccine treatments present new possibilities for the delivery of novel therapeutics, beyond the world of infectious disease.

For full access to this content, please Register or Sign In.

Access Content Vaccine Potential And Preclinical Development Needs
Newsletter Signup
Newsletter Signup